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SUMMARY
Metastasis may arise years after removal of a primary tumor. The mechanisms allowing latent disseminated
cancer cells to survive are unknown. We report that a gene expression signature of Src activation is associ-
ated with late-onset bonemetastasis in breast cancer. This link is independent of hormone receptor status or
breast cancer subtype. In breast cancer cells, Src is dispensable for homing to the bones or lungs but is crit-
ical for the survival and outgrowth of these cells in the bonemarrow. Src mediates AKT regulation and cancer
cell survival responses to CXCL12 and TNF-related apoptosis-inducing ligand (TRAIL), factors that are
distinctively expressed in the bone metastasis microenvironment. Breast cancer cells that lodge in the
bone marrow succumb in this environment when deprived of Src activity.INTRODUCTION
Distant metastasis is the final and most threatening stage of
malignant tumor progression, but its clinical course and biolog-
ical features vary extensively depending on the type of cancer.
One of the most striking variables in metastasis is its latency.
In some types of cancer, metastasis occurs soon after a primary
tumor develops, whereas in others it emerges years or even
decades after the primary tumor is removed (Karrison et al.,
1999; Schmidt-Kittler et al., 2003; Weckermann et al., 2001).
During such long latency periods the disseminated cancer cells
survive maladapted to the host organ microenvironment, either
in a dormant state or as indolent micrometastases, until they
eventually meet all the requirements for metastatic outgrowth.
The long-term permanence of latent metastatic disease implies
the existence of mechanisms that keep the disseminated cancercells alive. The identification of mechanisms that support the
survival of disseminated cancer cells in their host microenviron-
ments has clear implications for understanding the biology and
improving the treatment of latent metastatic disease.
Latent metastasis leading to late-onset relapse occurs
frequently in breast cancer. Nearly one-third of cases of relapse
emerge after 3 years of breast cancer diagnosis, with some
cases emerging several decades later (Karrison et al., 1999;
Schmidt-Kittler et al., 2003). A majority of these late-onset
metastases arise in bone and may subsequently appear in other
organs. Bone metastases from breast cancer are typically
osteolytic, involving the mobilization of osteoclasts that cause
pathological bone resorption, with intense pain, bone fractures,
nerve compression, and hypercalcemia (Mundy, 2002). The
development and osteolytic nature of these lesions are based
on complex interactions between cancer cells and bone marrowSIGNIFICANCE
We sought to identify signaling pathways that support the survival of disseminated breast cancer cells and thereby extend
the period during whichmetastasis may emerge after the diagnosis and removal of a breast tumor. Based on bioinformatics
analyses, we discovered a strong association between late-onset bone metastasis and Src activity in a cohort of over 600
breast cancer patients. We further demonstrated that Src supports cancer cell survival in the bone marrow microenviron-
ment by facilitating CXCL12-CXCR4-AKT signaling and by conferring resistance to TRAIL. The link between Src-dependent
signaling and metastatic cell survival provides mechanistic insights into metastasis latency, and suggests strategies to
hasten the attrition of disseminated breast cancer cells.Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc. 67
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Figure 1. Src Responsive Signature in Breast Tumors Is Associated with Bone Metastasis
(A) Kaplan-Meier representation of the probability of cumulative overall metastasis-free survival in 615 breast cancer cases according to the estrogen receptor
a (ER) status. The numbers of tumors in each category, the total metastasis events, the late-onset (>5 yrs) metastasis events, and the corresponding p values (log
rank test) are shown in the embedded table.
(B) Same as in (A), but bone metastasis-free survival.
(C) Same as in (B), but cases are categorized according to their SRS status.
(D) Hierarchical clustering of 615 primary tumors with known bonemetastasis outcomes by ER status, SRS status, andmolecular subtypes. Redmarks above the
heat map indicate tumors that develop bone metastasis.stroma in a cycle of bone destruction and tumor expansion. The
complexity of cellular interactions and molecular components
implicated in bone metastasis has hindered a mechanistic eluci-
dation of key biological features of this process, in particular the
basis for long-term survival of metastatic cells in the bone
marrow (Husemann et al., 2008; Stoecklein et al., 2008).
Src is the prototypic member of a nonreceptor tyrosine kinase
family. Its action on mammalian cells is broadly pleiotropic,
including effects on cell morphology, adhesion, migration, inva-
siveness, proliferation, differentiation, and survival. Src partici-
pates in the activation of various downstream pathways through
molecular interactions with growth factor receptors (EGFR,
HER2), integrin cell adhesion receptors, steroid hormone recep-
tors, G protein-coupled receptors, focal adhesion kinase, and
cytoskeleton components (Bromann et al., 2004; Ishizawar and
Parsons, 2004). Aberrant expression and activation of Src occurs
inseveral tumor typesandhasbeencorrelatedwithpooroutcome,
whichhasstimulated interest inSrckinase inhibitorsas therapeutic
agents in cancer, some of which have entered clinical trials (Finn,
2008; Rucci et al., 2008; Summy and Gallick, 2006). This knowl-
edge notwithstanding, studies to date have not pinned specific
roles of Src in particular aspects of tumor development in humans.
Gene expression profiling techniques that can register the activity
of signaling pathways provide new tools to search for links
between specific pathways and defined steps of tumor progres-
sion (Bild et al., 2006; Klapholz-Brown et al., 2007; Padua et al.,
2008). Using this approach, we are reporting here on an associa-
tionbetweenSrcpathwayactivity and late-onsetbonemetastasis.68 Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc.RESULTS
Src Activity in Breast Tumors Is Associated
with Late-Onset Bone Metastasis
To investigate the association of pathway-specific gene expres-
sion signatures with breast cancer outcome we assembled
a combined cohort of 615 breast tumors for which genome-
wide gene expression data was available. Approximately two-
thirds of these cases were lymph node negative at diagnosis,
and were not subject to adjuvant therapy after primary tumor
resection (Wang et al., 2005; Yu et al., 2007). The rest of cases
were lymph node positive or received adjuvant hormonal the-
rapy and/or chemotherapy (Table S1). Among the 615 cases,
43% relapsed, and the median metastasis-free survival time
was 22.1 months. ER+ cases had a longer disease-free interval
and a lower rate of recurrence during the first 20 months
compared with the ER cases (Figure 1A). The rate of late-onset
metastasis (defined as relapse >5 years after cancer diagnosis)
was significantly higher in ER+ cases. The overall incidence of
metastasis in ER+ and ER casesmerged over time. These char-
acteristics fit with the typical course of breast cancer progres-
sion (EBCTCG, 2005; Hess et al., 2003).
ER+ breast tumors relapsemost prominently to the bones over
a protracted period (Hess et al., 2003). Indeed, the overall rate of
bonemetastasis and the rate of late-onset bonemetastasis in the
615 breast cancer patients were significantly higher in ER+ cases
than in ER cases (Figure 1B). Reasoning that this metastatic
latency may depend on a particular cell survival pathway, we
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the activity of specific pathways, including the Src, H-Ras, E2F3,
Myc,b-catenin (Bild et al., 2006), TCF/Wnt (van deWetering et al.,
2002), and TGFb pathways (Padua et al., 2008). Notably, a gene
expression signature that denotes Src activity (designated as
Src-responsive signature, SRS) was tightly associated with
overall bone metastasis and late-onset of bone metastasis
(Figure 1C). Bone relapsewasmore closely associatedwithSRS+
status than with ER+ status (p = 7 3 109 versus p = 0.001 for
overall bone relapse; p = 0.0002 versus p = 0.003 for late-onset
metastasis, log rank test). When we repeated the analysis after
excluding patients who died from other metastases, SRS status
was still strongly associated with overall bone metastasis (p =
6.4 3 106) and late-onset bone metastasis (p = 0.0037). The
only other pathway that showed an associationwith bone relapse
was the H-Ras pathway, but this association was marginal (p =
0.04; Table 1). The TGFb response signature in primary tumors
Table 1. Association of Pathway Gene Expression Signatures
with Metastasis in Breast Cancer
Bone Lung Brain All
Src (SRS) <1e-6 0.98 0.54 0.62
H-Ras 0.04 0.03 0.674 0.05
E2F3 0.09 0.52 0.84 0.04
b-Catenin 0.06 0.98 0.22 0.32
Myc 0.42 0.1 0.07 0.36
TGFb 0.27 0.008* 0.80 0.02
TCF4/WNT 0.19 0.11 0.02 0.15
The activity of seven signaling pathways was assessed in a cohort of 615
human breast tumors based on previously defined gene expression
signatures (Bild et al., 2006; Padua et al., 2008; van de Wetering et al.,
2002). Correlations with site of metastasis were determined using
a Cox hazard ratio regression model or by log rank test. Bold numbers
indicate correlations that reach statistical significance. Italic numbers
indicate a negative correlation (better prognosis).
*The TGFb response signature (TBRS) is associated with lung relapse
specifically in ER tumors (p = 0.002 within the ER subset in this cohort;
Padua et al., 2008).was associated with lung but not bone relapse (Table 1), as
reported (Paduaetal., 2008).Breast tumorscompriseaheteroge-
neous mix that includes several molecularly distinct subtypes
(Sorlie et al., 2003). All of these subtypes were represented
among the SRS+ tumors (Figure 1D).
Amajority (88.4%) of ER+ tumors in this cohort scored as SRS+
(Figure 1C; Table S2). Indeed, Src and ERa engage in molecular
interactions that lead to nontranscriptional effects (Collins and
Webb, 1999; Ishizawar and Parsons, 2004). However, 23.0%
of ER tumors also scored as SRS+, providing us with an oppor-
tunity to discern whether Src activity is specifically linked to bone
metastasis independent of ER+ status. The ER status of these
tumors was confirmed based on microarray ERa probe signal
(Figure S1). Because the vast majority of bone relapses in ER
cases occur before 5 years, we decided to use a less stringent
>3-year cutoff to define ER bone metastases that occur rela-
tively late. Indeed, a multivariate analysis based on the Cox
proportional hazard model indicated that the hazard ratio of
SRS+ patient starts to dramatically increase 3 years after tumor
resection, and remains at comparable levels at 4-year and
5-year cutoffs (Figure 2A). We therefore decided to use 3 years
as the cutoff for late-onset bone metastasis in the particular
case of ER patients. Compared with ERSRS tumors, the
ERSRS+ tumors showed a higher incidence of bone metastasis
and late-onset bone metastasis (p = 0.003, Figures 2B and 2C,
log rank test). ERSRS+ cases developed bone metastasis
with rate and kinetics that were similar to those of ER+SRS+
cases (Figures 2B and 2C). Conversely, when the analysis was
restricted within the SRS+ or SRS subsets, ER status was no
longer correlated with bone relapse (p = 0.33 and p = 0.69 for
SRS and SRS+ groups, respectively; Figure 2B).
Multivariate analyses showed that the association of SRS+
status with bone relapse and/or late-onset bone relapse was
independent of progesterone receptor (PR) status, HER2 status,
molecular subtypes, genomic grade index, and differentiation
(Sotiriou et al., 2006; Tables S3–S5). A subset of the patients
was subject to adjuvant therapies (Table S6), but a multivariate
analysis showed that SRS associates with bone metastasis
independently of either hormonal or chemotherapy (Table S7).A B C
Figure 2. SRS Defines a Subset of ER Patients that Develop Delayed Bone Metastases
(A) Hazard ratios of SRS status and ER status on late-onset bone metastasis when these parameters are fit into a bivariate Cox proportional hazard regression
model. Various cutoffs from 0 to 5 years were used to define late-onset bone metastasis. Error bars and standard error as determined by the statistical model.
p values assess the significance of the hazard ratio’s difference from 1 (no prognostic value). *p < 0.05; **p < 0.001; ***p < 105.
(B) Kaplan-Meier representation of bone metastasis-free survival. Tumors are categorized according to both ER status and SRS status. p values based log rank
tests.
(C) Histograms of bone metastasis onsets in the indicated categories of tumors.Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc. 69
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brain relapse (Table S8). An association between SRS status
and liver metastasis was of marginal significance (p = 0.035)
and limited to ER+ patients. For some patients, metastases
occurred to multiple organs, which were diagnosed at the same
time. These patients were scored for each of the corresponding
sites in our analyses. This potentially confounding factor made
little impact to the current study, because fewer than 20% of
the patients with late-onset bone metastases also developed
metastases to other sites. Collectively, these observations
suggest a specific link between SRS+ status and late-onset
relapse to bone in breast cancer.
Src Selectively Promotes Bone Metastasis
Because ERSRS+ breast tumors indicated an ER-independent
association between Src activity and bone metastasis, we
sought to identify a suitable ERSRS+ metastatic model system
to further investigate this link. MDA-MB-231 (MDA231 for short)
is a cell line derived from the pleural fluid of an ER breast cancer
patient with disseminated disease. MDA231 is a basal subtype,
triple-negative (ER, PR, HER2) cell line (Neve et al., 2006). By
in-vivo selection, we previously isolated MDA231 cell popula-
tions with distinct metastatic organ tropisms in mice (Kang
et al., 2003; Minn et al., 2005). Gene expression profiles from
these derivatives were subjected to SRS analysis. The parental
MDA231 population as well as various bone metastatic and
adrenal gland metastatic derivatives showed higher SRS scores
than did the lung metastatic and brain metastatic derivatives
(Figure 3A; Figure S2). The level of activated (Tyr416-phosphor-
ylated) Src (Thomas and Brugge, 1997) was higher in represen-
tative bone and adrenal metastatic MDA231 derivatives than in
lung and brain metastatic derivatives (Figure 3B).
To test the role of Src activity in bone metastasis, we stably
reduced the level of endogenous Src using a shRNA vector in
the MDA231 bone metastatic derivative BoM-1833 (Kang
et al., 2003). shRNA-mediated knockdown reduced the level of
endogenous Src and of activated Src by >90% (Figure 3C). We
also generated a Src-rescued BoM-1833 line expressing this
shRNA and the chicken Src gene, which is resistant to the
shRNA. On injection of 3 3 104 cells into the left ventricle, all
mice in the BoM-1833 control group were dead with bone
metastasis within 70 days. Knockdown of Src extended survival
by 25 days, whereas Src rescue reversed this gain (Figure 3D).
We monitored the kinetics of emergence of hind-limb bone
lesions by quantitative bioluminescence imaging (BLI) of lucif-
erase activity from a stably integrated vector. The control, Src
knockdown, and Src-rescued BoM-1833 cells localized to the
bones and initiated outgrowth at similar rates for up to 14 days
(Figures 3E and 3F). However, from day 21 after injection, the
rate of outgrowth of the bone lesions in the Src knockdown
group decreased, becoming 10-fold lower than that of the
control groups (Figure 3F). This difference was accompanied
with a sharp reduction in the extent of the hind-limb osteolytic
lesions, as determined by X-ray imaging and histological exam-
ination (Figure 3E). Knockdown of two other Src family kinases,
Fyn and Yes, did not inhibit the bone metastatic activity in
BoM-1833 cells (Figure S3).
Src knockdown did not decrease the intrinsic proliferative
activity of BoM-1833 cells in culture (Figure S4), or their growth70 Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc.as tumors in mammary glands (Figure 3G). Src knockdown had
no effect on the limited lung-metastasis activity of these ortho-
topic BoM-1833 tumors (Figure 3G). Using the highly lung-meta-
static MDA231 derivative line LM2-4175 (Minn et al., 2005) we
additionally tested the effect of Src knockdown using tail-vein
inoculation assays, which test for lung colonization activity
(Figure 3H). The knockdown of Src had no effect on lung tumor
burden. These observations pointed to a selective and specific
role of Src in bone metastasis.
Src EnhancesMetastatic Outgrowth in the BoneMarrow
Microenvironment
The kinetics of BoM-1833 bone colonization suggested a role of
Src in the sustained outgrowth of these colonies. Indeed, when
directly inoculated into the bone marrow cavity of tibiae and
tracked for tumor outgrowth, the Src-depleted cells were
approximately 10-fold less active than control cells, and this inhi-
bition was rescued by Src expression (Figures 4A and 4B). Dasa-
tinib (BMS-354825) is a pharmacological inhibitor of Src family
tyrosine kinases (Shah et al., 2004). Administration of dasatinib
at 10 mg/kg daily by oral gavage (Kamath et al., 2008) after in-
oculation of BoM-1833 cells in mice significantly prevented the
formation of osteolytic metastases (Figure 4C). An inhibitory
effect was observed when dasatinib treatment was started
7 days or 14 days after cancer cell inoculation. Dasatinib had
no effect on the lung colonizing activity of LM2-4175 cells
(Figure S5).
Dasatinib inhibits various Src family kinases, and Src is func-
tionally important in various cell types in the bonemarrow stroma
(Abram and Lowell, 2008). To establish the specificity of the
dasatinib effect onbonemetastasis,we stably expressedadasa-
tinib-resistant mutant form of Src (Du et al., 2009) in Src knock-
down BoM-1833 cells. The bone metastatic activity of BoM-
1833 could be inhibited by dasatinib when the Src knockdown
was rescued with the wild-type Src but not when it was rescued
with the dasatinib-resistant Srcmutant (Figure 4D). Thus, genetic
and pharmacological evidence argued that Src activity is
dispensable for bone marrow seeding by MDA231 cells but is
rate limiting for the sustained growth of these colonies.
Src has been implicated in cancer cell proliferation and
survival, and in osteoclast differentiation (Horne et al., 2005;
Lowell et al., 1996). Lesions formed by Src knockdown BoM-
1833 cells contained a high proportion of apoptotic (TUNEL+)
cells compared with bone lesions formed by control BoM-1833
cells, whereas this proportion in Src-rescued BoM-1833 lesions
was low and comparable to that in the controls (Figure 4E;
Figure S6). Administration of dasatinib also induced a high
level of TUNEL+ cells. By contrast, Src knockdown and dasatinib
treatment had no effect on the proportion of proliferating (Ki67+)
cancer cells (Figure 4F), or of tartrate-resistant acid phosphatase
(TRAP+) osteoclasts located at the tumor-bone matrix interface
(Figures 4G and 4H). These results suggest that Src supports the
aggressive outgrowth of BoM-1833 cells by promoting their
survival in the bone marrow microenvironment.
Src Supports Survival of Indolent Breast Cancer Cells
in Bone Marrow
Because BoM-1833 cells are a model of acute bone metastatic
colonization, we also tested the role of Src in a more indolent
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Figure 3. Src Selectively Promotes Bone Metastasis
(A) Metastasis organ-tropism and SRS activity of in vivo-selected MDA231 derivatives cell lines. The blue-white-red shows a single value score of SRS activity
determined by principal component analysis of the expression of the 159 genes that constitute the SRS. Cell lines were ordered by unsupervised hierarchical
clustering with the SRS genes (refer to Figure S2).
(B) Representative MDA231 derivatives were subjected to western immunoblotting with the indicated antibodies. Organ tropism: 1833, bone; 831, brain; 4175,
lung; and 1834, adrenal.
(C) Knockdown of Src in BoM-1833 as confirmed by western immunoblotting analysis.
(D) Survival of mice after intracardiac injection (3 3 104 cells) with BoM-1833 transduced with a control vector (Control), a Src shRNA vector (Src RNAi), or Src
shRNA and shRNA-resistant Src expression vectors (Rescued). (n = 15–20 per group).
(E) Bioluminescent, radiographic, and H&E analysis of bone lesions from representative mice in each group at the indicated times after inoculation. In the X-ray
images, areas of bone lysis are indicated by dotted lines. In the H&E staining, asterisks indicate tumor.
(F) Normalized bioluminescence signal of bonemetastases in the hind limbs of mice inoculatedwith the indicated cell lines. The signal intensities were normalized
to day 0, which was set arbitrarily as 100. Data are averages ± SEM. p value calculated using Student’s t test with Welch correction.
(G) Left panel: The indicated cell lines (5 3 105 cells) were injected into the cleared fourth mammary fat pad of mice. Tumor sizes were measured at day 35 (n =
7–10 in each group). Right panel: Quantification of lung metastasis burden originated from the orthotopic mammary tumors. Data are averages ± SEM.
(H) LM2-4175 cells (23 105 cells) expressing a control vector (LM2 control) or a Src shRNA vector control (LM2-Src RNAi) were injected into the tail vein of mice.
Lung colonization was assayed by weekly bioluminescence imaging. Plots show normalized photon flux in the lung over time (n = 5 per group). Representative
H&E stained lungs 5 weeks after xenografting are shown. Src knockdown was confirmed by western immunoblotting. Data are averages ± SEM.model of bone metastatic disease. From the pleural fluid of
a breast cancer patient we isolated a malignant cell population,
termed CN34, which was ER (Figure S7A). CN34 cells trans-
duced with a luciferase/GFP vector and a puromycin-resistant
marker yielded one bone lesion after 9weeks of intracardial inoc-
ulation in five mice. Extraction of these cells and expansion in
culture, followed by two additional cycles of selection as bone
lesions, yielded CN34-BoM2 derivatives. Compared with a
CN34-BrM2c derivative that is metastatic to brain but not bone
(data not shown), CN34-BoM2 cells showed a higher level ofactivated Src (Figure 5A). However, compared with BoM-1833
cells, CN34-BoM2 cells grow in the bone marrow at a 100-fold
lower rate (Figure 5B). CN34-BoM2 cells are also metastatic to
lymph nodes (Figure 5C; Figure S7). Src knockdown CN34-
BoM2 cells (refer to Figure 7A) were almost devoid of bonemeta-
static activity, whereas the Src-rescued counterparts recovered
the lost activity (Figure 5B). By contrast, Src knockdown did not
inhibit lymph node metastasis (Figure 5C; Figure S7).
To test the effect of Src on survival under even more-indolent
conditions, we inoculated mice with a low number (5 3 104) ofCancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc. 71
Cancer Cell
Bone Metastasis Latency Mediated by SrcA
E F G
H
B C D
Figure 4. Src Enhances Metastasis Survival and Outgrowth in Bone Marrow
(A) Growth of the indicated cell lines after direct implantation into the marrow of tibia. Quantitative bioluminescence was done at day 35. Averages ± SEM (n = 10
per group).
(B) Representative bioluminescence imaging and H&E staining of bone lesions of each experimental group in (A) at day 35.
(C) BoM-1833 cells were injected into left cardiac ventricle of mice, and animals were treated with vehicle control (mock) or dasatinib (10 mg/kg) daily starting on
days 0, 7, or 14 after inoculation. The plot shows quantitative bioluminescence values of the hind limb region at day 35. Data are averages ± SEM (n = 10 per
group).
(D) Vectors encodingwild-type Src or dasatinib-resistantmutant Src were used to rescue the expression of Src in BoM-1833 cells that also expressed Src shRNA.
On day 7 after intraventricular inoculation, animals were treated with vehicle control or dasatinib. Day 35 average bioluminescence ± SEM (n = 10 per group).
(E) Size-matched femoral metastases from mice inoculated with control, Src knockdown, or Src-rescued BoM-1833 cells, or with BoM-1833 cells and treated
with dasatinib (starting on day 7), were extracted on day 35 (control and Src-rescued groups) or day 56 (dasatinib and Src RNAi groups). Samples were subjected
to TUNEL staining. Four or more randomly picked fields were quantified, and the percent of TUNEL-positive cells ± SEM is plotted.
(F) The samples in (E) were subjected to staining and quantification of Ki-67 proliferation marker. n.s., not significant. Data are averages ± SEM.
(G) The samples in (E) were TRAP stained to identify presumptive osteoclasts at the tumor-bone matrix interface. Arbitrary units were assigned to represent the
proportion of red TRAP-staining cells. n.s., not significant. Data are averages ± SEM.
(H) Representative TRAP staining. Arrows indicate positive staining.control or Src knockdown CN34-BoM2 cells. No BLI signal
developed above background (<104 photons per second) in
35 days. The bone marrow was flushed from the femurs of
these mice and placed in culture under puromycin selection
(Figure 5D). The resulting colonies expressed GFP and were
stained positive for human vimentin, confirming that these were
the human tumor-derived cells (Figure 5E). Compared with mice
inoculated with control CN34-BoM2, mice inoculated with Src
knockdown CN34-BoM2 yielded 9-fold fewer bone marrow-
derived human cell colonies (Figure 5F). Thus, Src was required
for the survival of these indolent breast cancer cells in the bone
marrow.
Cell-Survival Factors in the Bone Metastasis
Microenvironment
In light of these results, we postulated that Src may be required
for the response of breast cancer cells to survival factors
provided by the bonemarrowmicroenvironment. To identify rele-
vant factors, we conductedmicroarray gene expression analysis
on a cohort of metastasis samples that were surgically removed72 Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc.from breast cancer patients at Memorial Sloan-Kettering Cancer
Center (MSKCC), including 16 metastases from bone, 18 from
lung, 19 from brain, and 5 from liver. Analysis of SRS status
showed that 62.5% (10/16) of bonemetastaseswereSRS+ (Table
S9), in agreement with a report that the majority of breast cancer
cells in bone metastases immunostain positive for activated Src
(Planas-Silva et al., 2006). Only 28.6% (12/42) of metastases to
other sites scored SRS+. Of 260 cytokines and chemokines
(compiled by Gene Ontology database, ID GO:0005125) in these
samples, we focused on those that are expressed in bonemetas-
tases at a higher level (>2-fold) than in metastases from other
sites. Seventeen genes met these criteria (Figure 6A). These
genes include the chemokine CXCL12/SDF1, which is produced
bybonemarrowmesenchymal cells andacts as anattractant and
survival factor for cells expressing the receptor CXCR4 (Muller
et al., 2001). Also included are insulin-like growth factors (IGFs),
bonemorphogenetic protein-2 (BMP2), and transforming growth
factors b (TGFbs), which are stored in the bone matrix and
released during osteolysis (Guise et al., 2006; Mundy, 2002).
IGFs stimulate survival in various cell types (Stewart andRotwein,
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Figure 5. Src Supports Survival of Indolent Breast Cancer Cells in Bone Marrow
(A) Src and activated (Y416 phosphorylated) Src protein levels in parental, bone-tropic (BoM2), and brain-tropic derivatives (BrM2c) of CN34 cells, as determined
by western immunoblotting of cell lysates.
(B) Normalized bioluminescence signal intensity at the hind limbs of mice that were intracardially inoculated with the indicated cell lines (1 3 105 cells). Data are
averages ± SEM (n = 8–10 per group).
(C) Normalized bioluminescence signal intensity at the upper back region of the same mice, to capture lymph node metastasis signal. Data are averages ± SEM.
(D) Schematic of assay to determine the survival of breast cancer cells in the bone marrow.
(E) Samples (53 104 cells) were intracardially injected in 7-week-old mice. Surviving tumor cells were extracted and grown as shown in (D). Images show immu-
nofluorescence staining of representative colonies with the indicated antibodies. Scale bar, 50 mm.
(F) Quantification of latency-derived human breast cancer cell colonies. Data are averages ± SEM (n = 3 per group).1996),whereasBMPsandTGFbsare implicated in thegeneration
of osteoblasts and osteoclasts, respectively (Chen et al., 2004).
Other factors of interest that were selectively expressed in
bone metastasis tissues include platelet-derived growth factor-
A (PDGF-A), placenta growth factor (PGF), and vascular-endo-
thelial growth factor-C (VEGF-C), which are potential survival
and microenvironment-modifying factors, and the proapoptotic
member of the tumor necrosis factor family TRAIL (TNF-related
apoptosis-inducing ligand; encoded by TNFSF10) (Ashkenazi,
2002).
To determinewhether a similar profile of cytokines is present in
our experimental model, BoM-1833 cells were injected in high
A
B
Figure 6. Cytokines of the Bone Metastasis Microenviron-
ment
(A) Microarray gene expression analysis of 58 human breast cancer
metastasis samples revealed 17 cytokines whose expression was
upregulated in a majority of bone metastases but not in a majority of
metastases to lung, liver, or brain.
(B) Cytokine expression in metastases from mice inoculated with
MDA231 cells that are metastatic to bones, brain, or lungs. Lesions
were extracted from mice on day 28 and qRT-PCR was performed
for mouse genes encoding Cxcl12, Trail, Igf1, Pegfa, Vegfc, and
Tgfb1. Expression levels relative to the mean of the values in bone
metastasis are shown for each sample. Data are averages ± SEM.Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc. 73
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Figure 7. Src Mediates CXCL12-Dependent Survival and Resistance to TRAIL Death Signals in Breast Cancer Cells
(A) The indicated cell lines were incubated with or without CXCL12 for 30min. Immunoblots using the indicated antibodieswere performed onwhole-cell extracts.
P-AKT, phosphorylated (activated) AKT.
(B) TUNEL assays were performed 3 days after culturing the indicated cell lines in serum-free medium supplemented with CXCL12 or TRAIL. Data are averages ±
SEM (n = 6).
(C) Cell viability assays were performed by culturing BoM-1833 cells in serum-freemedium supplemented with CXCL12 (for 5 days) or TRAIL (for 3 days). Data are
averages ± SEM (n = 6).
(D) Immunoblots using the indicated antibodies were performed on whole-cell extracts from the indicated BoM-1833 derivatives after incubation with or without
TRAIL in the media.
(E) Upper panel: Schematic representation of the role of Src in the survival of breast cancer cells that infiltrate the bone marrow. Breast tumors that disseminate
Src-activated cancer cells have an advantage for long-term survival in the bone marrow microenvironment. Src influences the responsiveness of breast cancer
cells to specific bone metastasis microenvironment factors, CXCL12, and TRAIL. CXCL12 (also known as SDF1) binding to its receptor CXCR4 triggers AKT acti-
vation, and we show that Src is required for this activation and its associated prosurvival effects. Src activity is also required for the resistance of breast cancer
cells to the cell-death effect of TRAIL. Lower panel: Schematic representation of the course of breast cancer metastasis. After disseminated from the primary
tumors, cancer cells may infiltrate different organs. Disseminated cancer cells may survive in the form of latent disease for decades before eventually gaining
competence to outgrow and colonize the host tissue through the production of the osteoclastogenic factors.numbers (5 3 105 cells) to exploit their residual lung and brain
metastatic activity of this cell line in addition to the bone meta-
static activity. qRT-PCR assays of bone, brain, and lung metas-
tases formed by BoM-1833 xenografted in mice confirmed that
CXCL12, IGF1, PDGF-A, VEGF-C, and TGFb1 were more abun-
dantly expressed in bone metastases than in metastasis to brain
or lungs (Figure 6B). TRAIL was expressed at a higher level in
bone and lung metastases than in brain metastases.
Src Mediates CXCL12-Dependent Survival
and Resistance to TRAIL Death Signals
CXCL12 signaling through CXCR4 activates several signaling
pathways, including AKT (Epstein, 2004). Src has been indepen-
dently implicated in the activation of the cell-survival AKT kinase
(Lu et al., 2003). CXCR4 is consistently expressed at a high level
in our cell line systems and in a majority of human bone metas-
tases (Kang et al., 2003). Indeed, the addition of CXCL12 to
BoM-1833 and CN34-BoM cells under serum-free conditions
caused AKT activation, and this activation was diminished by
Src knockdown cells and restored by rescuing Src expression74 Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc.(Figure 7A). When cultured in serum-free medium, BoM-1833
and CN34-BoM cells undergo apoptosis after 2 days (BoM-
1833) or 5 days (CN34-BoM). CXCL12 significantly reduced
apoptosis under these conditions, whereas Src depletion
prevented this prosurvival effect (Figure 7B). Concordantly,
CXCL12 enhanced cell viability in a Src-dependent manner
(Figure 7C). Among the other cytokines enriched in the bone
metastasis samples, IGF1 induced Src-independent AKT activa-
tion (Figure S8) but Src-dependent survival (data not shown),
and TGFb1, BMP2, PDGF-A, and VEGF-C had little or no effect
on either AKT activation or cell survival (Figure S8; data not
shown).
Because the proapoptotic cytokine TRAIL was abundantly
expressed in bone metastasis tissue, we tested whether Src
plays a role in protecting the bone metastatic cancer cells from
TRAIL-induced cell death. TRAIL induces caspase activation
and apoptosis by binding to cell death receptor DR4 and DR5
(Ashkenazi, 2002). DR5 is expressed in our cell line systems
and in bone metastases (Affymetrix HG-U133A raw intensity
range 300–600 after MAS5.0 normalization with global scaling
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Bone Metastasis Latency Mediated by Srcfactor set to 500). TRAIL addition caused a small increase in
the level of activated caspase-3 (Figure 7D) and apoptosis in
BoM-1833 cells (Figure 7B), and a small decrease in cell viability
(Figure 7C). Notably, the knockdown of Src strongly increased
the sensitivity of BoM-1833 cells to these proapoptotic effects
of TRAIL, and this increase was reversed by the rescue of Src
expression (Figures 7B–7D). These results argue that in bone
metastatic breast cancer cells, Src is required for AKT activation
and cell survival in response to CXCL12, and for resistance to the
proapoptotic effect of TRAIL.
DISCUSSION
The presentwork provides clinical and experimental evidence for
a role of Src as a critical mediator of survival signals in breast
cancer cells that infiltrate the bonemarrow. Srcmediates survival
responses of breast cancer cells to CXCL12 and TRAIL—factors
that are prominently expressed in the bone metastasis microen-
vironment (Figure 7E). Strategies to suppress the survival of
disseminated cancer cells can be envisioned based on these
results.
Src Activity Linked Late-Onset Bone Metastasis
in Breast Cancer
Using gene expression signatures that denote activation of
specific pathways we show that expression of a Src response
signature (SRS) in primary breast tumors is associated with
late-onset bone metastasis. Among 615 cases that we analyzed,
nearly 15%of bone relapses fromSRS+ tumors occurred 5 years
after diagnosis, versus none in SRS tumors. This association
occurs in breast tumors of different subtypes and independently
of regional spread or adjuvant therapy. Although most ER+
breast tumors are SRS+, and estrogen receptors can interact
with Src (Ishizawar and Parsons, 2004), the link of SRS status
with bone metastasis is independent of ER status. Nearly one
quarter of all ER tumors in this cohort are SRS+, and this
subset also shows a high incidence of late bone metastasis.
The association of SRS+ status with bone metastasis is more
striking than the association of ER+ status with bone metastasis,
and the same applies to the association with late-onset bone
metastasis.
Our evidence suggests a more robust and sustained ability
of SRS+ breast cancer cells to develop bone metastases. A
majority of breast cancer bone metastases show activated Src
by immunostaining (Planas-Silva et al., 2006), and we show
that Src hyperactivity endows breast cancer cells with a superior
ability to persist in the bonemarrowmicroenvironment. Although
Src has well-characterized effects on cell motility and invasion
(Dehio et al., 1995), and the Src knockdown BoM-1833 cells
showed decrease in these activities in vitro, no effect of Src on
bone metastasis seeding was manifest in vivo. That most ER+
tumors are SRS+, and thus may derive a survival advantage in
the bone marrow microenvironment, is consistent with previous
evidence that interactions with estrogen receptor-a activate Src
(Migliaccio et al., 2002). Themechanism for Src activation in ER
breast cancer cells remains unknown but could involve receptor
tyrosine kinases, G protein-coupled receptors, integrins, and
focal adhesion kinase (Bromann et al., 2004; Guo and Giancotti,
2004; Ishizawar and Parsons, 2004; Mitra and Schlaepfer, 2006).Src-Dependent CXCL12 Survival Signals in the Bone
Marrow Microenvironment
Our results suggest a cell-autonomous, prosurvival role of Src in
breast cancer cells in the bone marrow microenvironment. Anal-
ysis of human breast cancer metastasis tissues revealed a group
of 17 secreted factors that are selectively expressed in bone
metastases but not in lung, liver, or brain metastases. We show
that the prosurvival effect of one of these factors, CXCL12, on
metastatic breast cancer cells requires Src. CXCL12 signals
through the heterotrimeric G protein-coupled receptor CXCR4
(Epstein, 2004), which is clinically and experimentally implicated
in breast cancer metastasis to bone (Kang et al., 2003; Liang
et al., 2005; Muller et al., 2001). CXCR4 is highly expressed in
BoM-1833 and other bone metastatic MDA231 derivatives
(Kang et al., 2003) and in clinical bone metastasis samples.
CXCR4 (Chinni et al., 2006) and Src (Lu et al., 2003) have been
implicated in the activation of the AKT cell survival pathway.
Our finding that Src is required for CXCL12 activation of AKT
and cell survival in bone metastatic breast cancer cells provides
a common thread for these various observations.We additionally
show that Src activity is required for resistance of metastatic
breast cancer cells to the proapoptotic effects of TRAIL. Through
the death receptors and activation of the extrinsic proapoptosis
pathway, TRAIL mediates immune surveillance and antitumor
cytotoxicity by dendritic cells, monocytes, NK cells, and effector
T cells (Ashkenazi and Herbst, 2008). By mediating CXCL12
survival signals and protecting against TRAIL cell death signals,
Src provides a cell-autonomous prosurvival function in cancer
cells that infiltrate bone marrow.
Bone Marrow Infiltration, Cancer Cell Survival,
and Metastatic Colonization
Breast tumors are competent for early dissemination and infiltra-
tion of distant organs (Husemann et al., 2008; Stoecklein et al.,
2008) but, unlike other types of tumors (e.g., lung adenocarci-
noma, pancreatic carcinoma), the disseminated breast cancer
cells often lack the competence for immediate metastatic
outgrowth (Figure 7E). Years may pass before aggressive bone
colonization occurs through the expression of osteoclastogenic
factors and other mediators (Guise et al., 2006; Kang et al.,
2003; Mundy, 2002; Yin et al., 1999). We suggest that by
enhancing the responsiveness of breast cancer cells to bone
marrow survival factors, Src extends the endurance of dissemi-
nated cancer cells, thereby increasing the probability of acquisi-
tion of full metastatic competence (Figure 7E). Other survival
mechanismsmay support latency in other organs (e.g., the lungs)
or in other late-onset metastasis cancers (e.g., prostate carci-
noma), although bone-derived secondary metastases to other
organs are also possible.
Despite effective systemic treatments, including chemo-
therapy, hormone therapy, and monoclonal antibody therapy,
high-risk subsets of patients continue to have unacceptable
rates of relapse in the bone and other organs (Hayes et al.,
2007; Hudis, 2007). High-dose chemotherapy in combination
with autologous hematopoietic stem-cell support has not shown
a benefit in high-risk breast cancer patients compared with
conventional standard-dose chemotherapy (Zander et al.,
2004). At present, the major clinical benefits from postoperative
adjuvant drug therapies are observed in the first few years afterCancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc. 75
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partially resistant to conventional therapy (Berry et al., 2006).
Disseminated cancer cell pools may act as reservoirs that
are resistant to such treatments but potentially susceptible to
treatments targeting mediators of latent cancer cell survival.
Our data raise the possibility that we might be able to use such
agents to attack reservoirs of disseminated latent cancer cells,
including circulating tumor cells or mitotically dormant tumor
cells in various organs. Consistent with this is the fact that
current chemotherapy and hormone-directed drugs do not
specifically target Src. Recently, however, several agents that
target Src pathways have become available for clinical testing
(Finn, 2008; Rucci et al., 2008; Summy and Gallick, 2006). This
approach could involve the use of Src inhibitors, TRAIL-receptor
agonists (Ashkenazi and Herbst, 2008), or other latency-targeted
agents either simultaneously with adjuvant drug regimens or
afterwards in order to achieve long-term maintenance of
disease-free status.
EXPERIMENTAL PROCEDURES
Additional methods for cell culture assays; quantitative real-time PCR; immu-
noblotting; generation knockdown and overexpression cell lines; details of
tumor xenografting; histological analyses; long-term survival assays; and
statistical analyses are provided in Supplemental Data.
Primary Tumor and Metastasis Tissue Samples
Wecompiled amicroarray dataset of 615patients fromMemorial Sloan-Ketter-
ing Cancer Center (MSKCC) and ErasmusMedical Center (EMC344, EMC189,
and MSK82; GEO accession numbers GEO2603, GSE5327, GSE2034, and
GSE12276). These datasets were all normalized using MAS5.0, and each
microarray was centered to the median of all probes. For each patient, metas-
tasis-free survival (MFS) is defined as the time interval between the surgery and
the diagnosis of metastasis.
Archival human breast carcinomametastasis specimens were obtained and
processed in compliance with protocols approved by the MSKCC Institutional
Review Board. Samples were snap frozen in liquid nitrogen and stored at
80C. Each sample was examined histologically using hematoxylin and
eosin-stained cryostat sections. Regions were manually dissected from the
frozen block to provide consistent tumor cell content of greater than 70%
in tissues used for analysis. RNA was extracted from frozen tissues by homo-
genization in TRIzol reagent (Gibco-BRL, Carlsbad, CA) and evaluated for
integrity. Complementary DNA was synthesized from total RNA using a T7-
promoter-tagged-dT primer. RNA target was synthesized by in vitro transcrip-
tion and labeled with biotinylated nucleotides (Enzo Biochem, Farmingdale,
NY). Labeled target was assessed by hybridization to Test3 arrays (Affymetrix,
SantaClara,CA). All geneexpression analysiswascarried out usingHG-U133A
(for 36 samples) or HG-U133plus2 (for 29 samples) GeneChips. Seven samples
were profiled on both platforms, and the data were averaged for the common
probes. Gene expression was quantitated using GCOS.
Molecular Pathway Gene Expression Signatures
To predict pathway activation frommicroarray gene expression data, we used
gene expression profiles derived from the overexpression of Src, H-Ras, b-cat-
enin, E2F3, andMyc inquiescentmammaryepithelial cells (Bild et al., 2006).We
derived a gene signature-expression classifier for each of these pathways
using a false discovery rate of 0.05 and a fold change of 1.5 as criteria. The
605genes thatmet these thresholds in theSrc responsivegenesetwere filtered
by using the EMC-344 data set to eliminate noninformative genes. After elimi-
nating genes that were either expressed at a low level (raw intensity <64 or 26 in
more than 25% tumors) or nonvariable across samples (SD < 0.8 for log2 inten-
sity, equivalent to themedian of all genes), 159genes remained and constituted
the Src responsive signature (SRS) used here.
The SRS was applied to EMC-344 and MSK-82 data sets, which are based
on HG-U133A and were combined, and to EMC-189 data set, which is based76 Cancer Cell 16, 67–78, July 7, 2009 ª2009 Elsevier Inc.on HG-U133plus2 and was processed separately. To search for breast
cancers with SRS expression pattern similar to the Src-activated mammary
epithelial cells (Bild et al., 2006) we performed unsupervised clustering (using
‘‘heatmap.2’’ function in gplots package of R statistical software). Two clusters
were consistently revealed by such procedure (R index = 0.85) (McShane et al.,
2002). One cluster was identified as SRS+ based on the criteria that it exhibits
gene expression similarity to Src-activated mammary epithelial cells as
gauged by positive Pearson’s correlation coefficients, ‘‘metagene’’ scores
(Bild et al., 2006), and that it enriches ER+ tumors (Collins and Webb, 1999;
Ishizawar and Parsons, 2004). The other cluster showed the opposite charac-
teristics and was denoted as SRS.
The same approach was applied for b-catenin, E2F3, H-Ras, and c-Myc
pathways. TGFb pathway was gauged as previously described (Padua et al.,
2008). For TCF/Wnt pathway, we performed unsupervised clustering using
the dominant negative TCF4 signature (van de Wetering et al., 2002). One of
the two clusters significantly overexpresses the vast majority of the dnTCF4
genes, and tumors in this cluster are therefore defined as TCF/Wnt+.
To examine the prognostic value of SRS in different subsets of breast
cancers, we divided the breast cancer samples based on their ER status or
molecular subtypes. For ER status, we used either published pathological
annotations (for GSE2063, GSE5327, and GSE2034) or the intensity of probe
‘‘205225_at’’ (ESR1) on the Affymetrix chip when the pathological status was
not available (for GSE12276). We used raw intensity of 1000 as the cutoff to
define ER versus ER+. It has been established that this is an appropriate
cutoff when the data is normalized with MAS5.0 and the global scaling is set
to 600 (Foekens et al., 2006). Molecular subtype classification was done as
previously described (Smid et al., 2008) according to published classifiers
(Perou et al., 1999; Sorlie et al., 2003). Of note, a nontrivial proportion of luminal
tumors cannot be unambiguously determined between luminal A and luminal B
subtypes. We therefore merged the two subtypes in some analyses.
Survival analyses were carried out using the ‘‘survival’’ package of R.
P values were calculated by the ‘‘survdiff’’ command in the package, which
is based on log rank tests. When sample size is small, we also performed
Fisher’s exact test. Kaplan-Meier curves were drawn with the ‘‘survfit’’
command in the same package. The Cox proportion hazard regression anal-
yses were performed using the ‘‘coxph’’ method in the same package.
Cytokine Gene Expression Analysis
We compiled a list of 260 cytokine genes using GO database (cytokine activity
entry: GO:0005125). These cytokines were mapped to 404 probes on the
Affymetrix HG-U133A platform. We screened these probes in each tissue
sample for those whose intensity value was greater than the median of all
genes, and statistically overexpressed in bone metastasis samples compared
with other metastasis (t test with Welch’s correction, p < 0.05 with correction
for multiple tests).
Tumor Xenografts and Analysis
All procedures involving mice were approved by the MSKCC Institutional
Animal Care and Use Committee. Details are provided in Supplemental Data.
Statistical Analysis
Bone metastasis assay in BoM-1833 line was repeated twice (n = 7–10 for
each cohort at each time). The results were pooled and shown as Figures
3D–3F. The same result was reproduced independently later in two additional
experiments. For the bone metastasis assay of CN34-BoM2 (Figure 5), lung
colonization assay (Figure 3H), orthotopic proliferation (Figure 3G), intratibial
growth (Figure 4A), and dasatinib treatment (Figures 4C and 4D), one experi-
ment was performed with n = 10–15 in each cohort. Results are reported as
mean ± SEM, as indicated in the figure legends. Comparisons between
Kaplan-Meier curves were performed using the log rank test. Other compari-
sons were performed using unpaired two-sided t test without equal variance
assumption unless otherwise specified.
ACCESSION NUMBERS
The raw and normalized data of breast cancer metastases have been depos-
ited in the Gene Expression Ominbus (GEO) database under accession
number GSE14020.
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